NEW DRUGS

Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma

JHOP - April 2021 Vol 11, No 2 - FDA Updates, Multiple Myeloma
Download PDF

On March 27, 2021, the FDA approved idecabtagene vicleucel (Abecma; Bristol Myers Squibb/Bluebird Bio), a B-cell maturation antigen (BCMA)-directed, genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or recurred, after ≥4 lines of therapy.

Idecabtagene vicleucel is the first BCMA-directed CAR T-cell therapy approved for the treatment of multiple myeloma. The FDA granted this indication orphan drug and breakthrough therapy designations.

“While there is no cure for multiple myeloma, the long-term outlook can vary based on the individual’s age and the stage of the condition at the time of diagnosis. Today’s approval provides a new treatment option for patients who have this uncommon type of cancer,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.

According to the National Cancer Institute, in 2020 multiple myeloma accounted for approximately 1.8% (N = 32,000) of all new cancer cases in the United States.

The FDA approved idecabtagene vicleucel based on results of a multicenter study of 127 patients with relapsed or refractory multiple myeloma after ≥3 lines of therapy. Approximately 88% of the patients had received ≥4 lines of therapy.

Overall, 72% of patients had a response to the study drug, including 28% complete responses. Of the patients with complete responses, 65% had a complete response lasting ≥12 months.

The most common side effects of idecabtagene vicleucel include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system. Side effects usually appear within the first 1 or 2 weeks after treatment, but some may occur later.

Severe side effects associated with idecabtagene vicleucel include CRS, hemophagocytic lymphohistiocytosis or macrophage activation syndrome, neurologic adverse events, and prolonged cytopenia, all of which can be fatal or life-threatening. Because of such serious side effects, idecabtagene vicleucel is only available through a REMS program. The FDA is also requiring the manufacturer to conduct a postmarketing observational study to validate the long-term safety of the drug.

Related Items
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Skin Cancer
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Myelosuppression
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Vyxeos Now Indicated for Pediatric Patients with AML
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Leukemia, Pediatric Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lung Cancer
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.